ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Nurse Practitioner

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,059Medicare Part D Prescriptions Filled, Including Refills

Rank: 3 out of 53

$358K Total Retail Price of All Prescriptions

Rank: 4 out of 53

910 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
17% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 910 patients filled at least one prescription for a schedule two drug, compared to an average of 13%.

Schedule Three
Controlled Substances

13% of this provider’s 910 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

2% of this provider’s 8,233 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

15% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$36 was the average price of a prescription from this provider, compared to $71 among peers.

Prescriptions per Patient

11 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
SIMVASTATIN 579 533 1 4
OMEPRAZOLE 496 413 2 5
LISINOPRIL 473 426 3 2
LEVOTHYROXINE SODIUM 442 388 4 3
HYDROCODONE-ACETAMINOPHEN 362 257 S3 5 1
AMLODIPINE BESYLATE 295 276 6 7
ATENOLOL 245 206 7 17
METFORMIN HCL 216 193 8 6
CITALOPRAM HBR 201 161 9 19
ALENDRONATE SODIUM 190 186 10 24
ZOLPIDEM TARTRATE 189 155 11 12
LOVASTATIN 186 168 12 8
LOSARTAN POTASSIUM 174 134 13 15
HYDROCHLOROTHIAZIDE 165 131 14 14
GABAPENTIN 156 129 15 9
FLUTICASONE PROPIONATE 146 125 16 31
VENTOLIN HFA 142 115 17 32
METOPROLOL TARTRATE 140 123 18 13
LISINOPRIL-HYDROCHLOROTHIAZIDE 133 115 19 58
METOPROLOL SUCCINATE 125 92 20 45
TERAZOSIN HCL 125 125 20 91
PRAVASTATIN SODIUM 123 79 22 35
OXYCODONE HCL 111 55 S2 23 16
FUROSEMIDE 107 94 24 11
ALLOPURINOL 90 83 25 43
FENOFIBRATE 90 78 25 71
POTASSIUM CHLORIDE 87 73 27 21
PREDNISONE 85 69 28 23
TAMSULOSIN HCL 82 73 29 50
RANITIDINE HCL 82 72 29 46
POLYETHYLENE GLYCOL 3350 82 64 29 53
MORPHINE SULFATE ER 81 28 S2 32 18
QVAR 80 67 33 112
WARFARIN SODIUM 78 75 34 10
TRAMADOL HCL 78 67 34 34
DILTIAZEM ER 72 71 36 116
GLYBURIDE 72 47 R 36 73
METFORMIN HCL ER 68 42 38 91
GLIPIZIDE ER 67 55 39 57
HYDRALAZINE HCL 63 55 40 56
FINASTERIDE 62 61 41 129
CARISOPRODOL 60 0 R 42 30
OXYBUTYNIN CHLORIDE ER 58 51 43 137
CARVEDILOL 54 52 44 52
IBUPROFEN 50 41 45 40
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 8, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.